RxElite, Inc.
RXEI · OTC
9/30/2008 | 6/30/2008 | 3/31/2008 | 12/31/2007 | |
|---|---|---|---|---|
| Revenue | $3 | $3 | $3 | $1 |
| % Growth | 8.4% | 0.2% | 155.2% | – |
| Cost of Goods Sold | $3 | $3 | $3 | $1 |
| Gross Profit | $0 | $1 | $0 | -$0 |
| % Margin | 9.4% | 16.7% | 11.9% | -14.4% |
| R&D Expenses | $0 | $0 | $0 | $1 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $3 | $3 | $2 | -$1 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $5 | $4 | $3 | $0 |
| Operating Income | $5 | $3 | $2 | $0 |
| % Margin | 138.7% | 102.3% | 82.5% | 36.1% |
| Other Income/Exp. Net | -$6 | -$3 | -$4 | -$5 |
| Pre-Tax Income | -$1 | $0 | -$2 | -$5 |
| Tax Expense | $6 | $3 | $5 | $0 |
| Net Income | -$11 | -$6 | -$7 | -$5 |
| % Margin | -336.6% | -212.6% | -234.7% | -411.8% |
| EPS | -0.094 | -0.055 | -0.061 | -0.055 |
| % Growth | -71.4% | 10.3% | -11.9% | – |
| EPS Diluted | -0.094 | -0.055 | -0.061 | -0.055 |
| Weighted Avg Shares Out | 117 | 116 | 115 | 89 |
| Weighted Avg Shares Out Dil | 117 | 116 | 115 | 89 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $4 | $1 | $0 | $0 |
| EBITDA | $5 | -$3 | $2 | -$0 |
| % Margin | 166% | -83.6% | 75.6% | -15.9% |